Publications by authors named "K Ichinose"
Rituximab (RTX) has been reported to effectively maintain remission in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In this multicenter study involving 57 patients who achieved remission after 24 weeks, we evaluated the effectiveness of RTX in maintaining remission in patients with AAV. Patients were divided into three groups based on RTX administration: continuous, induction phase-only, and maintenance phase-only groups.
View Article and Find Full Text PDFObjective: To assess the prevalence and outcomes among regimens of glucocorticoid tapering for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in real-world practice.
Methods: We retrospectively examined the Japan Collaborative Registry of ANCA-associated Vasculitis (J-CANVAS) registry, and evaluated the prevalence of glucocorticoid tapering regimens in the PEXIVAS trial. In patients with newly diagnosed MPA and GPA, we compared outcomes among standard and reduced pace regimens.
Background: Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in patients undergoing immunosuppressive therapy, such as glucocorticoid (GC) medication, for systemic autoimmune diseases like systemic lupus erythematosus (SLE). Despite the confirmed effectiveness of PCP prophylaxis, its clinical administration, especially in conjunction with GC dosage, remains unclear. We aimed to describe the clinical practice of PCP prophylaxis in association with SLE in Japan, evaluate the relationship between GC dosage and PCP prophylaxis, and explore the practice patterns associated with PCP prophylaxis.
View Article and Find Full Text PDFArticle Synopsis
- Enhanced ADAM9 expression in the kidneys of lupus nephritis patients can activate TGFβ1, leading to fibrosis and organ damage.
- Research showed that ADAM9 is upregulated in kidney tubular epithelial cells (TECs) under hypoxic conditions, contributing to TGFβ1 activation.
- Experiments with Adam9-deficient mice revealed less fibrosis, suggesting that targeting ADAM9 could be a potential strategy to reduce kidney damage in lupus nephritis.
Article Synopsis
- The study focuses on late-onset systemic lupus erythematosus (LoSLE) in Japan, highlighting its unique characteristics compared to early-onset systemic lupus erythematosus (EoSLE), which complicates diagnosis.
- Data from the Lupus Registry in Japan were analyzed, comparing patients with LoSLE (50+ years old at onset) to those with EoSLE (under 50), revealing differences in symptoms and demographics, such as a higher male-to-female ratio in LoSLE patients.
- Key findings indicated that LoSLE patients had a higher occurrence of myositis, lower occurrences of skin rash and alopecia, and distinct treatment patterns, with more EoS